Skip to main content

Braveheart Bio, Inc.

corporate_fare Company Profile

Braveheart Bio, Inc.

BRVE·NASDAQ·Life Sciences·CIK 0002131524

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company that develops treatments for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. The company's primary products are BHB-1893 and HRS-1893, which are oral small-molecule cardiac myosin inhibitors (CMIs). These therapies are designed to treat both obstructive HCM and non-obstructive HCM. Braveheart Bio, Inc. was incorporated in 2024 and operates from its base in San Francisco, California.

Braveheart Bio, Inc. (NASDAQ:BRVE) is a publicly traded company in the Life Sciences sector. Wiseek monitors BRVE SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Braveheart Bio Prices Upsized $382.5M IPO at $18/Share, Trading Tomorrow

show_chartPrice Chart

Loading chart...

feed BRVE - Latest Insights

BRVE
Aug 05, 2026, 10:33 PM EDT
Source: GlobeNewswire
Importance Score:
8
Braveheart Bio Prices Upsized $382.5M IPO at $18/Share, Trading Tomorrow
Sentiment: Positive
View Wiseek Article